Výsledky vyhledávání - "Howard E. Kaufman"

A retrospective study of ipilimumab plus nivolumab in anti–PD-L1/PD-1-refractory merkel cell carcinoma

Autor: Sophia Z. Shalhout, Kevin S. Emerick, Howard E. Kaufman, David M. Miller

Publikováno v: Journal of Clinical Oncology. 40:9521-9521

9521 Background: Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine carcinoma with a high recurrence and mortality rate. Immune checkpoint inhibitors (ICIs) targeting the PD-L1/PD-1 axis have shown significant clinical benefit with durabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30fd720db709869133d994167c575062
https://doi.org/10.1200/jco.2022.40.16_suppl.9521

Zobrazit plný text záznamu

A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies

Autor: Huan J. Zhu, Howard E. Kaufman, Haifang Jiang, Xusha Zhou, Andrew Haydon, Ganessan Kichenadasse, John M. Kirkwood, Elizabeth I. Buchbinder, Huinan Xu, Minal A. Barve, Jiaxin Niu, Dongyao Ni, Vinod Ganju

Publikováno v: Journal of Clinical Oncology. 39:2526-2526

2526 Background: T3011 is a genetically modified, next-generation oncolytic HSV-1 with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody. Locally produced IL-12 induces

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9123a340fcb23ad52eca1028138009a9
https://doi.org/10.1200/jco.2021.39.15_suppl.2526

Zobrazit plný text záznamu

The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma

Autor: Krista M. Rubin, Moshe Sade-Feldman, Florian J. Fintelmann, Ryan J. Sullivan, Riley Fadden, Meghan J. Mooradian, Mari Mino-Kenudson, Jaimie L. Barth, Donald P. Lawrence, Dennie T. Frederick, Howard E. Kaufman, Aleigha Lawless, Tatyana Sharova

Publikováno v: Journal of Clinical Oncology. 39:9538-9538

9538 Background: Percutaneous image-guided cryoablation (cryo) is an established minimally invasive oncologic treatment that modulates the immune microenvironment. We hypothesized that cryo can augment anti-tumor responses in melanoma patients progre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::638fbc059a504c3acf172e00e326a49d
https://doi.org/10.1200/jco.2021.39.15_suppl.9538

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání